6 news items
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
CADL
FGEN
ONCY
12 Jun 24
and atezolizumab. The main goals are to measure how well the treatments work and their safety. Additionally, the study will look at progression-free survival (how
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments
CADL
FGEN
ONCY
12 Jun 24
. The main goals are to measure how well the treatments work and their safety. Additionally, the study will look at progression-free survival (how long
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO
REGN
23 May 24
., Senior Vice President, Translational and Clinical Oncology at Regeneron. "Our costimulatory bispecifics were designed with the goal of turning cancer
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
REGN
17 May 24
to improve our world. Since 2020, Regeneron has provided STEM experiences to approximately 2.4 million students, on track to meet its goal of 2.5 million
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
REGN
17 May 24
our world. Since 2020, Regeneron has provided STEM experiences to approximately 2.4 million students, on track to meet its goal of 2.5 million by 2025
6t6gtqaghxyvyftsd2ss 03aa2ymrqd6giw7v368qjekw30ll
REGN
17 May 24
, Regeneron has provided STEM experiences to approximately 2.4 million students, on track to meet its goal of 2.5 million by 2025. "The talent
- Prev
- 1
- Next